Navigation Links
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Date:1/26/2009

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increa
'/>"/>

SOURCE Cell Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
6. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
8. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
9. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
10. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
11. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Leading events organizer UBM Live announces that ... year to São Paulo, Brazil from ... event will co-locate with Food Ingredients South America (FiSA), creating ... for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... are now exploring the South America ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today announced ... Center at the University,of Rochester, will present data ... in multiple sclerosis at the,upcoming American Academy of ... on Wednesday May 2, 2007 at 4:15 pm,Eastern ...
... Full Study Results,to Be Presented at the American ... ,WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) ... of its lead drug,candidate, AGI-1067, did not show ... however, it did achieve a number of,other important ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... of Dangerous Synthetic Marijuana Increasing (7/3), the state of ... synthetic marijuana, more so even than cocaine. Officials believe the ... safe because it's a “form” of marijuana. However, both doctors ... truth. Going so far as to call it “poison,” doctors ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... As reported by Wood TV 8 in ... Michigan has seen a nearly 500-person increase in heroin related ... was 271 between 1999 and 2002, the toll increased to ... like other states, drug users in Michigan have turned to ... He compared the price of both substances, noting that an ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... executives who have almost 50 years of hospital negotiating experience. Our ... a focus of expertise to help buyers become even more effective. ... all hospital purchases. There is finally help. , ... ...
... rituximab causes considerable kidney injury healing in patients with ... to a study appearing in the November 2008 issue ... Nephrology (CJASN) . The results suggest that this condition, ... percent of cases, can actually be healed in some ...
... Ill., Aug. 5 Healthation CEO Scott Kornhauser,announced ... Services. Collins brings to Healthation more than 20 ... include Vice President of Professional Services of,Aptiv Technology ... will be focused on leading, recruiting, and managing ...
... of Princeton psychology researchers has developed a computer program ... what it is about certain human faces that makes ... they have also found that the program allows them ... or dominant faces possible. , Such work could have ...
... carts from Eagle MHC are designed for maximum cleanability and sterile ... ... -- http://www.eaglegrp.com/ [Steril-Eze® surgical case carts] from Eagle MHC ... product line - which encompasses a wide range of choices in ...
... (NPF) announced it will fund $3.7 million in ... outreach worldwide.,Grants were awarded to institutions in the ... care centers, and 10 outreach,centers. Through centers alone, ... and almost 70,000 patients with movement disorders., ...
Cached Medicine News:Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease 2Health News:Whom do we fear or trust? 2Health News:Whom do we fear or trust? 3Health News:New Steril-Eze Surgical Case Carts from Eagle MHC Feature Rugged, Easy-Clean Design 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2
... and Only 16-Electrode Non-Rechargeable ... of RESTORE with the convenience of ... unrivaled RESTOREPRIME. The ultimate non-rechargeable device, ... managing patients with bilateral and complex ...
... a rechargeable neurostimulator equipped with a battery ... a 9-year FDA approved battery life. It ... market. This is helpful to people who ... What makes RESTOREADVANCED and PRIMEADVANCED different from ...
... is an acellular dermal matrix derived from ... AATB-compliant tissue banks utilizing the standards of ... and Food and Drug Administration's (FDA) guidelines. ... and not significantly changed in structure from ...
... a modular external fixation system designed to ... clinical needs. Originally marketed in Europe under ... 20 year history of clinical use in ... principles of the Ilizarov technique begun in ...
Medicine Products: